1. Virani SS, Alonso A, Aparicio HJ, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2021 Heart disease and stroke statistics update fact sheet at-a-glance. Accessed May 12, 2021.
  2. Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. NCHS Data Brief. 2018;328:1-8.
  3. American Heart Association. Cardiovascular disease: a costly burden for America. Projections through 2035. Accessed May 10, 2021.
  4. American Heart Association. HDL (good), LDL (bad) cholesterol and triglycerides. Accessed May 10, 2021.
  5. Centers for Disease Control and Prevention. Women and heart disease. Accessed May 10, 2021.
  6. Centers for Disease Control and Prevention. Heart disease facts: Accessed May 12, 2021.
  7. American Heart Association. Coronary artery disease – coronary heart disease. Accessed May 12, 2021.
  8. Salami JA, Warraich H, Valero-Elizondo J, et al. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiol. 2017;2(1):56-65.
  9. Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. BMJ Open. 2019;9(4):e023085.
  10. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
  11. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357-366.
  12. What you need to know about dietary supplements. US Food and Drug Administration website. Updated November 2017. Accessed May 10, 2021.
  13. Department of Health and Human Services. [Docket no. FDA–2016–N–1127]: AbbVie Inc., et al; Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Federal Register. April 18, 2016;81(74):22612-22613.
  14. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
  15. Kolber MR, Nickonchuk T, Turgeon R. Do PCSK9 inhibitors reduce cardiovascular events? Can Fam Physician. 2018;64(9):669.
  16. Rosenson RS, Hegele RA, Fazio S, Cannon CP. The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018;72(3):314-329.
  17. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;2013(1):CD004816.
  18. Pharmacy Times. FDA approves first PCSK9 inhibitor. Published July 24, 2015. Accessed May 10, 2021.
  19. MedPage Today. Second PCSK9 inhibitor approved for CV prevention. Accessed May 10, 2021.
  20. McClellan M, Brown N, Califf RM, Warner JJ. Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory from the American Heart Association. Circulation. 2019;139(9):e44-e54.
  21. Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health behaviour. Lancet. 2010;376(9748):1261-1271.
  22. Our World in Data. Does the news reflect what we die from? Published May 29, 2019. Accessed May 10, 2021.
  23. American Heart Association. Understand your risks to prevent a heart attack. Accessed May 10, 2021.
  24. National Institutes of Health. Atherosclerosis. Accessed May 10, 2021.
  25. Furie MB, Mitchell RN. Plaque attack: one hundred years of atherosclerosis in The American Journal of Pathology. Am J Pathol. 2012;180(6):2184-2187.
  26. Insull W JR. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009;122(1 Suppl):S3-S14.
  27. National Institutes of Health. Heart attack. Accessed May 10, 2021.
  28. National Institutes of Health. Stroke. Accessed May 10, 2021.
  29. National Institutes of Health MedlinePlus. Triglycerides test. Accessed May 10, 2021.
  30. American College of Cardiology CardioSmart. Very high triglycerides. Accessed May 10, 2021.
  31. ORIGIN Trial Investigators; Bosch J, Gerstein HC, Dagenais GR, et al. n–3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-318.
  32. Scherer J, Singh V, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195-203.
  33. National Institutes of Health MedlinePlus. Triglyceride level. Accessed May 10, 2021.
  34. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(suppl 1):S125-S150.
  35. National Center for Complementary and Integrative Health. Omega-3 supplements: in depth. Updated May 2018. Accessed May 13, 2021.
  36. Goel A, Pothineni NV, Singhal M, Paydak H, Saldeen T, Mehta JL. Fish, Fish Oils and Cardioprotection: Promise or Fish Tale? Int J Mol Sci. 2018;19(12):1-13.
  37. Aung T, Halsey J, Kromhout D, et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiol. 2018;3(3):225-234.
  38. Sherratt SCR, Mason RP. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochem Biophys Res Commun. 2018;496(2):335-338.
  39. Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care. 2016;25(1):46-52.
  40. Davidson MH. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013;24(6):467-474.
  41. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6(1):5-18.


if you are a healthcare professional

Click here to see the commercial.

Full Reference List |Disclaimer | Privacy Policy

The Amarin logo is a registered trademark of the Amarin group of companies. All other trademarks are the property of their respective companies.

© 2021 Amarin Pharma, Inc. Bridgewater, NJ, USA.
All rights reserved.
Contact Us: 1-855-CVTRUTH
The Amarin group of companies is not responsible for material contained on other non-Amarin controlled websites or other social media sites.
AMRN-00373v6   06/21